Literature DB >> 15981485

Naturally arising CD25+CD4+ regulatory T cells in tumor immunity.

T Nomura1, S Sakaguchi.   

Abstract

Naturally arising regulatory T (TR) cells, represented by CD25+CD4+ TR cells, play an essential role in maintaining immunological self-tolerance. This T cell-mediated dominant control of the immune response not only inhibits the development of autoimmune disease, but also impedes effective immunosurveillance against autologous tumor cells. Attenuation of TR cell-mediated immune suppression can therefore evoke effective tumor immunity in otherwise nonresponsive animals. This common regulatory mechanism for autoimmunity and tumor immunity can be exploited when devising a novel immunotherapy for cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15981485     DOI: 10.1007/3-540-27702-1_13

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  31 in total

Review 1.  Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment.

Authors:  Thomas F Gajewski; Mercedes Fuertes; Robbert Spaapen; Yan Zheng; Justin Kline
Journal:  Curr Opin Immunol       Date:  2010-12-23       Impact factor: 7.486

2.  CD137 costimulation of CD8+ T cells confers resistance to suppression by virus-induced regulatory T cells.

Authors:  Shelly J Robertson; Ronald J Messer; Aaron B Carmody; Robert S Mittler; Christopher Burlak; Kim J Hasenkrug
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

3.  Disruption of evasive immune cell microenvironment in tumors reflects immunity induced by radiation therapy.

Authors:  Alexander Filatenkov; Jeanette Baker; Samuel Strober
Journal:  Oncoimmunology       Date:  2016-02-26       Impact factor: 8.110

4.  Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.

Authors:  Pierpaolo Correale; Maria Saveria Rotundo; Maria Teresa Del Vecchio; Cinzia Remondo; Cristina Migali; Chiara Ginanneschi; Kwong Y Tsang; Antonella Licchetta; Susanna Mannucci; Lucia Loiacono; Pierfrancesco Tassone; Guido Francini; Pierosandro Tagliaferri
Journal:  J Immunother       Date:  2010-05       Impact factor: 4.456

Review 5.  Gut Microbiota, Inflammation, and Colorectal Cancer.

Authors:  Caitlin A Brennan; Wendy S Garrett
Journal:  Annu Rev Microbiol       Date:  2016-09-08       Impact factor: 15.500

6.  T-Cell Immunopeptidomes Reveal Cell Subtype Surface Markers Derived From Intracellular Proteins.

Authors:  Niclas Olsson; Liora M Schultz; Lichao Zhang; Michael S Khodadoust; Rupa Narayan; Debra K Czerwinski; Ronald Levy; Joshua E Elias
Journal:  Proteomics       Date:  2018-04-18       Impact factor: 3.984

7.  Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions.

Authors:  Alexander Filatenkov; Jeanette Baker; Antonia M S Mueller; Justin Kenkel; G-One Ahn; Suparna Dutt; Nigel Zhang; Holbrook Kohrt; Kent Jensen; Sussan Dejbakhsh-Jones; Judith A Shizuru; Robert N Negrin; Edgar G Engleman; Samuel Strober
Journal:  Clin Cancer Res       Date:  2015-04-13       Impact factor: 12.531

Review 8.  Molecular profiling of melanoma and the evolution of patient-specific therapy.

Authors:  Thomas F Gajewski
Journal:  Semin Oncol       Date:  2011-04       Impact factor: 4.929

9.  Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody.

Authors:  Masaki Terabe; Elena Ambrosino; Shun Takaku; Jessica J O'Konek; David Venzon; Scott Lonning; John M McPherson; Jay A Berzofsky
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

10.  An enteric pathogen Salmonella enterica serovar Typhimurium suppresses tumor growth by downregulating CD44high and CD4T regulatory (Treg) cell expression in mice: the critical role of lipopolysaccharide and Braun lipoprotein in modulating tumor growth.

Authors:  T Liu; A K Chopra
Journal:  Cancer Gene Ther       Date:  2009-08-28       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.